Home / Europe / Slovenia / Life Sciences & Healthcare

Life Sciences & Healthcare

With over 480 international specialist lawyers across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations we help shape the legal frameworks impacting the life sciences & healthcare sector.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice and compliance. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.


Feed

16/05/2023
Can­nabis law and le­gis­la­tion in Slov­e­nia
Med­ic­al use Since 2016, when can­nabis was re-cat­egor­ised with­in the De­cree on the clas­si­fic­a­tion of il­li­cit drugs, it has been per­mit­ted to use it for med­ic­al pur­poses in ac­cord­ance with the Medi­cin­al...
12/05/2023
Con­sulta­tion on the EU’s in­ter­im emis­sions re­duc­tion tar­get for 2040
Un­til 24 June 2023 the European Com­mis­sion is con­sult­ing to gath­er views on the EU’s cli­mate tar­get for 2040.Since the Com­mu­nic­a­tion of the European Green Deal in late 2019, there have been a raft of...
10/05/2023
At last: in­valid­ity and re­voc­a­tion ac­tions now avail­able be­fore TM of­fices...
One of the most sig­ni­fic­ant in­nov­a­tions in­tro­duced by the EU Trade Mark Dir­ect­ive 2015/2436 (the so-called trade mark re­form pack­age) was the re­quire­ment for all EU coun­tries to im­ple­ment – where not...
04/05/2023
Di­git­al health apps and telemedi­cine in Slov­e­nia
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Comparable
02/05/2023
CMS up­dates Ex­pert Guide on can­nabis law and le­gis­la­tion
CMS Ex­pert Guide on can­nabis law and le­gis­la­tion gives stake­hold­ers de­tailed and up­dated in­form­a­tion on the latest de­vel­op­ments in can­nabis reg­u­la­tion in key mar­kets. The Guide now cov­ers two new jur­is­dic­tions:...
13/04/2023
CMS series: At CEEnter stage
Our en­ga­ging pod­cast and video series, "At CEEntre Stage," is a valu­able re­source for pro­fes­sion­als and leg­al ad­visors seek­ing in-depth in­sights in­to vari­ous Cor­por­ate and M&A top­ics. Our series caters to di­verse busi­nesses in Cent­ral and East­ern Europe, provid­ing com­pre­hens­ive cov­er­age of the on­go­ing chal­lenges they face.Half-hour mod­er­ated dis­cus­sions with leg­al ex­perts and in­dustry lead­ers al­low us to gain valu­able in­sights in­to their vis­ion for the fu­ture, the chal­lenges they face, and ways to im­prove their busi­nesses. We also provide guid­ance on nav­ig­at­ing leg­al com­plex­it­ies and avoid­ing po­ten­tial traps, en­sur­ing our listen­ers re­ceive con­tex­tu­al­ized in­sights in­to the re­gion's dis­tinct­ive busi­ness land­scape and reg­u­lat­ory en­vir­on­ment.Our com­pre­hens­ive cov­er­age of vari­ous in­dus­tries and their on­go­ing chal­lenges makes "At CEEntre Stage" an es­sen­tial re­source for stay­ing ahead of the curve in today's fast-paced eco­nomy. The pod­cast cov­ers rel­ev­ant Cor­por­ate and M&A top­ics from W&I in­sur­ances, FDI to ESOP, joint ven­tures, fin­an­cing and ESG.Tune in to "At CEEntre Stage" today and stay in­formed on the latest in­sights and trends in the world of cor­por­ate law and M&A.
04/04/2023
European Com­mis­sion amends Art­icle 102 TFEU guid­ance pa­per and an­nounces...
In 2008, the Com­mis­sion ad­op­ted its Guid­ance on the Com­mis­sion`s en­force­ment pri­or­it­ies in ap­ply­ing Art­icle 82 of the EC Treaty (now Art­icle 102 TFEU) to ab­us­ive ex­clu­sion­ary con­duct by dom­in­ant un­der­tak­ings...
28/03/2023
European Par­lia­ment and Coun­cil ready to start ne­go­ti­ations on EU Data...
In Feb­ru­ary 2022 the European Com­mis­sion presen­ted its pro­pos­al for the EU Data Act, which – if ad­op­ted - will in­tro­duce a far-reach­ing leg­al re­gime on ac­cess to and use of non-per­son­al data in the...
20/03/2023
Out with the old, in with the new? Con­sid­er­a­tions for pat­entees in opt­ing...
So far in this series of blog posts, we began with an art­icle that high­lighted some of the key changes between the cur­rent European sys­tem of pat­ent pro­sec­u­tion and en­force­ment and the new Unit­ary Pat­ent...
16/03/2023
Mer­ger con­trol re­view be­low fil­ing thresholds – the ECJ Tower­cast judg­ment...
On 16 March 2023, the ECJ de­cided that a M&A trans­ac­tion, which was not sub­ject to ex-ante EU mer­ger con­trol, can be re­viewed – from an ex post per­spect­ive – as to wheth­er the ac­quirer (through the...
09/03/2023
Se­cur­ity for costs in en­force­ment pro­ceed­ings in Ger­many – The Ger­man Fed­er­al...
Pur­su­ant to Sec. 110 of the Ger­man Civil Pro­ced­ure Code (ZPO), claimants who do not have their ha­bitu­al place of res­id­ence in a mem­ber state of the EU/the EEA can be ordered to provide se­cur­ity for the...
09/03/2023
CMS Ex­pert Guide to ESG Com­pens­a­tion
In­cor­por­at­ing ESG KPIs in­to dir­ect­ors’ re­mu­ner­a­tionThe ur­gent need to place sus­tain­ab­il­ity at the heart of com­pany strategy is in­ex­tric­ably linked to in­cent­ives provided to its dir­ect­ors and em­ploy­ees. This...